The global extracorporeal membrane oxygenation machine market was valued at USD 307.9 million in 2023 and is projected to reach USD 445.7 million by 2030, expanding at a CAGR of 5.5% from 2024 to 2030. Market growth is primarily driven by the rising incidence of cardiopulmonary diseases and respiratory failures.
According to the Centers for Disease Control and Prevention (CDC), a person dies every 37 seconds from cardiovascular disease in the U.S., emphasizing the growing demand for advanced life-support technologies like ECMO systems. Additionally, chronic obstructive pulmonary disease (COPD), one of the leading causes of death in the U.S., continues to fuel market demand. As per the American Lung Association (2022), approximately 4.6% of adults, or 11.7 million people, reported a COPD diagnosis, highlighting the rising burden of respiratory conditions. In response, technological advancements have led to the development of hollow pumps, high-efficiency oxygenators, and heparin-coated cannulas, significantly improving ECMO system performance and versatility in surgical and critical care settings.
The increasing adoption of ECMO systems in hospitals and the expansion of awareness programs have been pivotal in driving market growth. Over the past 3–5 years, more than 100 new ECMO programs have been established in the U.S., bringing the total to around 300–400. This surge reflects growing clinical acceptance and broader access to ECMO therapy. In July 2022, Inspira Technologies OXY B.H.N. Ltd. launched the “Liby” System, a next-generation life support solution for patients suffering from severe heart and lung failure — marking a key milestone in ECMO innovation.
Technological progress has also led to the introduction of portable and compact ECMO machines, making them more adaptable across clinical settings and improving patient transport capabilities. The integration of miniaturized circuits and portable adapters has further expanded ECMO’s applications, especially for critical care transfers and emergency procedures.
Key Market Trends & Insights
- North America dominated the market in 2023, holding a 39.5% revenue share.
- The U.S. represented the largest share within North America.
- By component, the oxygenators segment held the largest share at 34.61% in 2023 and is projected to register the fastest CAGR during the forecast period.
- By modality, the veno-arterial segment accounted for the highest revenue share of 42.2% in 2023.
- By application, the respiratory segment led the market with a 44.10% share in 2023.
Download a free sample PDF of the Extracorporeal Membrane Oxygenation Machine Market Intelligence Study by Grand View Research.
Market Size & Forecast
- 2023 Market Size: USD 307.9 Million
- 2030 Projected Market Size: USD 445.7 Million
- CAGR (2024–2030): 5.5%
- North America: Largest market in 2023
- Asia Pacific: Fastest-growing market
Competitive Landscape
The ECMO machine market is characterized by a competitive mix of established players and emerging innovators. Leading companies are focusing on technological innovation, global expansion, and AI integration to enhance patient outcomes and broaden clinical applications. The demand for portable, smart, and telemedicine-integrated ECMO systems is shaping the next phase of market evolution. Established firms are also expanding into emerging regions to meet the growing demand for advanced life support solutions.
Recent Developments
- July 2023: BreathMo, an ECMO system based on maglev technology, was unveiled at the ASAIO Conference, marking a breakthrough in China’s domestic medical innovation.
- April 2023: Abbott received two new FDA clearances for its CentriMag Blood Pump, expanding its use for long-term ECMO support in adults with heart and lung complications.
- November 2022: LivaNova PLC secured FDA 510(k) clearance for its LifeSPARC circulatory support system, enabling broader clinical use in the U.S. market.
- July 2022: Inspira Technologies OXY B.H.N. Ltd. launched the “Liby” System, an advanced ECMO platform for patients with severe cardiopulmonary failure.
- July 2021: Xenios AG, a subsidiary of Fresenius Medical Care, received NMPA approval in China for its Xenios Console and patient kits, marking a key regulatory milestone in Asia.
Key Companies Profiled
- Medtronic Plc
- Maquet Holding
- MicroPort Scientific Corporation
- Terumo Cardiovascular System Corporation
- Medos Medizintechnik
- Nipro Medical Corporation
- LivaNova PLC
- CytoSorbents Corporation
- EUROSETS S.R.L
Explore Horizon Databook – the world’s most comprehensive market intelligence platform by Grand View Research.
Conclusion
The extracorporeal membrane oxygenation (ECMO) machine market is poised for steady growth, driven by rising cardiopulmonary disease prevalence, expanding hospital adoption, and continuous technological innovation. The development of compact, portable, and AI-enhanced ECMO systems is expected to revolutionize critical care, improve patient outcomes, and fuel market expansion through 2030.
No comments:
Post a Comment